Non-pharmacological Treatment for Nontuberculous Mycobacterial Pulmonary Disease

Hyung-Jun Kim[1,2*]

[1]Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea

[2]Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

[*]Correspondence to: Hyung-Jun Kim

Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital. 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea.

Tel: +82-31-787-7844; Fax: +82-31-787-4052; E-mail: dr.hjkim@snu.ac.kr

Abstract

Nontuberculous mycobacterial pulmonary disease (NTM-PD) arises from the exposure of susceptible hosts to a diverse group of environmental mycobacteria. The emphasis on non-pharmacological strategies is motivated by widespread presence of nontuberculous mycobacteria (NTM) in various environments and the inconsistent success rates of pharmacological treatments. Modifiable factors contributing to NTM-PD development include impaired airway clearance, low body mass index, gastroesophageal reflux disease, and exposure to NTM habitats. This suggests that lifestyle and environmental modifications could affect disease development and progression.

The review highlights several modalities that can modify the risk factors. Airway clearance techniques, informed by the "gel-on-brush" model of the bronchial epithelium, aims at enhancing mucociliary clearance and have potential in alleviating symptoms and potentially improving lung function. The impact of nutritional status is also examined, with a lower body mass index linked to an increased risk and progression of NTM-PD, indicating the importance of targeted nutritional support. Additionally, the theoretical and epidemiological links between gastroesophageal reflux disease and NTM-PD advocates for careful management of reflux episodes. Understanding the risk of NTM transmission through environmental exposure to contaminated water and soil is also crucial. Strategies to mitigate this risk, including effective water management and minimizing soil contact, are presented as vital preventive measures.

In conclusion, the review supports the inclusion of non-pharmacological treatments within a comprehensive NTM-PD management strategy, alongside conventional pharmacological therapies. This integrated approach seeks to improve the overall understanding and handling of NTM-PD.

Keywords: Nontuberculous Mycobacteria; Non-pharmacological Management; Lifestyle

Introduction

Nontuberculous mycobacteria (NTM) represent a diverse group of acid-fast bacilli, distinct from tuberculosis and leprosy bacteria, comprising over 200 species [1,2]. Despite this diversity, these organisms are categorized together due to specific phenotypic characteristics. Found in a variety of environmental settings, NTM can cause nontuberculous mycobacterial pulmonary disease (NTM-PD) through interactions between the host, environment, and microbe itself [3,4].

The necessity for non-pharmacological treatment against NTM-PD stems from several reasons. Firstly, ubiquity of NTM in the environment does not always result in disease. Its presence around and within us was demonstrated in a study where NTM was found in the nostrils, buccal samples, oropharynx, and dental plaque of healthy individuals [5]. The factors determining why these individuals do not develop NTM-PD point to the critical role of susceptible phenotypes, including impaired airway clearance, weakened immune responses, and other risk factors like gastroesophageal reflux disease (GERD) [6]. This suggests that modifiable factors could alter the disease course (Figure 1).

Secondly, the results from pharmacological treatments are less than satisfactory. The treatment success rates for *M. abscessus* pulmonary disease and *M. avium* complex pulmonary disease (MAC-PD) are relatively low, ranging from 33% to 60%, depending on the species [7,8]. Compounded by the adverse effects of anti-NTM drugs, patient adherence to guideline-based therapies is challenging. A study on 1038 participants in the US noted adverse effects in 21% of therapy recipients, with 33% discontinuing therapy [9]. Given that microbiological cure correlates with a better prognosis in MAC-PD [10], employing every possible strategy is essential.

Third, the process for species identification and drug susceptibility testing is time-consuming. Different NTM species exhibit varying levels of virulence and pathogenicity, making species identification crucial for selecting appropriate treatment regimens [11-13]. This period of

uncertainty underscores the need for patient education on appropriate behavior during the diagnostic interval.

Fourth, NTM-PD exhibits a variable clinical course. Studies have shown that a significant portion of patients with MAC-PD remain stationary without treatment, and some patients with *M. abscessus*-PD experience spontaneous culture conversion [14,15]. Although major guidelines recommend initiating treatment rather than observation [1,2,16], watchful waiting supplemented with non-pharmacological strategies can be a viable strategy considering the high rates of adverse reactions to antibiotics.

Despite the lack of specific recommendations in major guidelines for non-pharmacological treatment strategies against NTM-PD, evidence from observational studies and trials on similar diseases like tuberculosis and bronchiectasis provides valuable insights. Conducting randomized controlled trials for NTM-PD is challenging due to ethical concerns regarding the omission of non-pharmacological advice to patients, and the inherently low-risk nature of these treatments, which are intuitively beneficial. This review aims to recommend several non-pharmacological treatment strategies potentially beneficial for managing patients with NTM-PD (Tables 1–2).

Airway clearance techniques

Several known host factors increase the risk of developing NTM-PD, including underlying lung disease, impaired airway clearance, weakened immune response, low body mass index (BMI), female sex, and GERD [17-20]. Among these, only a few are modifiable, with impaired mucus clearance from the airways being a major modifiable risk factor.

The bronchial epithelia comprise a "gel-on-brush model," which consists of a mucus layer (gel)

and a periciliary layer (brush) [21]. When the concentration of the gel exceeds that of the brush, the cilia are compressed by osmotic pressure, leading to impaired airway clearance. Compared to normal controls, sputum from patients with bronchiectasis has a higher solid percentage, mucin, and osmotic pressure; however, the expression of mucin genes does not increase [22]. This suggests that hydrating the mucus could lower the concentration of "gel," which can facilitate better airway clearance. Introducing mechanical stress on the airway epithelia is crucial for promoting hydration. Oscillatory stress, in particular, has been shown to stimulate airway surface hydration and enhance mucociliary transport rates [23,24].

The application of mechanical stress to the airway epithelia has resulted in various airway clearance techniques [25]. Although these techniques may vary, the core mechanism involves creating oscillations to induce shear forces on the mucus layer and generating back-pressure that opens the airways and improves the delivery of air behind the mucus [26]. A randomized crossover study involving 20 patients with non-cystic fibrosis bronchiectasis concluded that the use of an oscillating positive expiratory pressure device led to decreased cough and increased exercise capacity, as well as greater sputum production, indicating enhanced airway clearance [27]. An observational retrospective review of 77 patients with NTM-PD found that airway clearance techniques were associated with improvements in cough, sputum production, and total lung capacity [28]. In practical terms, implementing pursed-lip breathing, huffing, active cough training, manual chest percussion, and the use of an oscillating positive expiratory pressure device can be effective.

Nutritional support

A lower BMI is associated with a higher incidence of NTM-PD [20]. Patients with NTM-PD often experience lifelong thinness, attributed to increased metabolic demand and anorexia resulting

from the symptoms of the disease and side effects of the medication. Lower BMI is linked not only to a higher disease incidence is but also one of the major factors leading to poorer prognosis [29]. Studies have shown that patients with NTM-PD have lower body fat, with a notable case-control study in the USA including 204 patients finding this trend in an osteoporosis-dominant group [30]. Another study in South Korea identified that decrease in cholesterol level is associated with NTM-PD progression [31]. The relationship between body fat and NTM-PD may be explained by changes in adipokine expression [32]. Leptin, primarily produced by white adipose tissue, enhances the adaptive immune response, activates T-helper 1 cells, and promotes IFN-γ release [33]. Conversely, adiponectin, which inversely relates to body fat, reduces TNF-α production, a cytokine protective against the host [34].

While direct interventional evidence of nutritional support on NTM-PD is scarce, insights from similar diseases are informative. A study in Spain involving 30 patients with non-cystic fibrosis bronchiectasis found that hyper-protein nutrition supplementation (330kcal with 18g of protein) improved muscle strength and quality of life [35]. Additionally, a large-scale cluster-randomized controlled trial in India, including household contacts of pulmonary tuberculosis patients, showed that providing food rations (750kcal with 23g of protein) reduced tuberculosis incidence by 39% [36].

Given the chronic underweight condition observed in NTM-PD patients, mere advice to “gain weight” may not suffice. Physicians should provide specific guidance, such as limiting non-caloric beverages, increasing caloric intake per meal, and consuming regular high-calorie snacks. Scheduling 4 to 6 small, frequent meals or snacks daily is recommended over consuming a single large meal [37]. Regarding protein intake, the 18 to 23 grams of protein can typically be met by consuming about four eggs, half a chicken breast, or three cups of milk [38].

Managing GERD

GERD has been linked to an increased incidence of NTM-PD [17]. The transmission of NTM from the environment to humans, particularly through waterborne pathways leading to NTM aspiration into the lungs following gastric reflux, supports this association [39,40]. Inherent resistance of *M. avium* to acidity underlines the potential role of GERD in NTM-PD development [41]. Consequently, the use of antacids, which could theoretically enhance NTM survival by reducing stomach acidity, warrants cautious consideration. A small case-control study found antacid use more common among MAC-PD patients, although causality remains uncertain [42].

Based on the current evidence, several recommendations can be formulated to minimize episodes of gastroesophageal reflux without diminishing stomach acidity. Dietary modifications are essential, specifically avoiding foods known to decrease lower esophageal sphincter pressure. Such foods include alcohol, caffeine, carbonated beverages, chocolate, citrus fruits, coffee, as well as fatty and spicy foods, garlic, onion, peppermint, and tomatoes [37]. Additionally, patients are advised to elevate the head of their bed or to sleep on their left side, which can help prevent nocturnal reflux. It is also recommended that patients remain in an upright position for a period after eating to allow gravity to assist in the digestion process. Finally, cessation of smoking is strongly recommended as it can significantly contribute to the reduction of GERD symptoms by improving the function of the lower esophageal sphincter and reducing reflux episodes [37,43].

Reducing exposure to NTM

Unlike tuberculosis bacteria, which infects only living hosts, NTM is widespread in soil and

natural water sources due to its unique biological characteristics [44]. The lipid-rich, hydrophobic surface of NTM aids in attaching to various surfaces and forming biofilms, thereby conferring resistance to disinfectants, antibiotics, and amoebae. Their ability to thrive in environments with low oxygen and carbon concentrations, as well as to withstand high temperatures, enables their survival in hot water systems and recirculating aqua systems.

NTM may be inhaled in aerosolized form from both water and soil (Figure 2). Studies among Medicare beneficiaries in the US have identified a higher prevalence of NTM -PD in regions characterized by significant daily evapotranspiration and extensive surface water areas [45]. Additionally, frequent soil exposure (≥2/week) has been linked with the presence of MAC-PD compared to controls [46]. Furthermore, NTM is not limited to outdoor environments; indoor exposure also poses a risk. A whole genome sequencing study conducted in South Korea provided concrete evidence of environmental transmission from indoor water sources to patients [47], while another study from the US revealed a higher presence of NTM in shower aerosols of MAC-PD patients compared to controls [48]. Exposure to water sources such as indoor swimming pools, rusty, or unclear tap water has also been associated with NTM-PD [49,50].

Several strategies can be employed to minimize exposure to NTM from environmental water sources. One effective method is to heat the water prior to use, as NTM populations are significantly reduced at temperatures exceeding 55 to 65°C. Given capacity of NTM to adapt to temperature changes, it may be advantageous to implement sudden alterations in water temperature to ensure its efficacy [51,52]. In regions like South Korea, where home boilers are prevalent, adjusting the hot water temperature to at least 65°C can provide additional safety. While point-of-use filters offer a potential solution, it is important to note that *M. avium* can proliferate in filters if exposed to water for more than three weeks [53]. Furthermore, purified

bottled water is not immune to NTM contamination [54], suggesting that boiling water remains the most reliable method for ensuring its safety from NTM (Table 2).

Mitigating exposure to NTM from environmental soil and dust involves relatively direct measures. Patients are advised to steer clear of activities that bring them into contact with soil, including gardening, farming, and tending to flowers. When avoidance is impractical, measures should be taken to prevent the aerosolization of soil into dust. Strategies such as moistening the soil with water to reduce dust generation or covering the soil can significantly reduce the risk of NTM exposure. To further reduce the risk of inhalation of dust and aerosols containing NTM, wearing appropriate masks during activities that generate dust can be an effective preventive measure (Table 2).

Conclusion

In this review, a variety of non-pharmacological treatment strategies for NTM-PD were examined. The "gel-on-brush" model highlights the role of hydration in facilitating effective airway clearance, with mechanical stress and oscillation playing key roles in enhancing mucociliary transport. These foundational techniques in airway clearance not only serve to alleviate symptoms but also offer the potential to enhance lung function. Furthermore, an observed trend of lower BMI among NTM-PD patients, associated with disease progression, points to a possible link with the altered expression of adipokines. Consequently, nutritional supplementation is presented as a viable strategy, leveraging its established benefits in the management of related conditions such as bronchiectasis and tuberculosis. The theoretical and epidemiological associations between GERD and NTM-PD underscore the necessity for patients to carefully manage reflux episodes, including the judicious use of antacids. Considering the ubiquitous presence of NTM in diverse environmental settings, implementing

strategies to minimize exposure to contaminated water and soil is deemed essential for infection risk reduction. This holistic management approach for NTM-PD advocates for the combination of lifestyle adjustments, dietary modifications, and environmental measures alongside conventional pharmacological therapies, aiming to provide a comprehensive strategy for the management of the disease.

Conflict of interests

None to declare

Acknowledgements

None to state

Funding

This review paper was not funded by any other organizations.

References

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
2. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Jr., Andrejak C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020;71:e1-e36.
3. Honda JR, Virdi R, Chan ED. Global Environmental Nontuberculous Mycobacteria and Their Contemporaneous Man-Made and Natural Niches. Front Microbiol 2018;9:2029.
4. Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol 2020;11:303.
5. Macovei L, McCafferty J, Chen T, Teles F, Hasturk H, Paster BJ, et al. The hidden 'mycobacteriome' of the human healthy oral cavity and upper respiratory tract. J Oral Microbiol 2015;7:26094.
6. Matsuyama M, Matsumura S, Nonaka M, Nakajima M, Sakai C, Arai N, et al. Pathophysiology of pulmonary nontuberculous mycobacterial (NTM) disease. Respir Investig 2023;61:135-48.
7. Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, et al. M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J 2019;54.
8. Kwak N, Park J, Kim E, Lee CH, Han SK, Yim JJ. Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis. Clin Infect Dis 2017;65:1077-84.
9. Ku JH, Henkle E, Aksamit TR, Barker A, Brunton AE, Winthrop KL, et al. Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US

Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines. Clin Infect Dis 2023;76:338-41.

10. Kim JY, Park J, Choi Y, Kim TS, Kwak N, Yim JJ. Microbiological Cure at Treatment Completion Is Associated With Longer Survival in Patients With Mycobacterium avium Complex Pulmonary Disease. Chest 2023;164:1108-14.

11. Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis 2016;45:123-34.

12. van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009;64:502-6.

13. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-8.

14. Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J 2017;49.

15. Jo KW, Park YE, Chong YP, Shim TS. Spontaneous sputum conversion and reversion in Mycobacterium abscessus complex lung disease. PLoS One 2020;15:e0232161.

16. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017;72:ii1-ii64.

17. Kim Y, Yoon JH, Ryu J, Yang B, Chung SJ, Kang HK, et al. Gastroesophageal Reflux Disease Increases Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease. Chest 2023;163:270-80.

18. Loebinger MR, Quint JK, van der Laan R, Obradovic M, Chawla R, Kishore A, et al.

Risk Factors for Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Literature Review and Meta-Analysis. Chest 2023;164:1115-24.

19. Rosain J, Kong XF, Martinez-Barricarte R, Oleaga-Quintas C, Ramirez-Alejo N, Markle J, et al. Mendelian susceptibility to mycobacterial disease: 2014-2018 update. Immunol Cell Biol 2019;97:360-7.

20. Song JH, Kim BS, Kwak N, Han K, Yim JJ. Impact of body mass index on development of nontuberculous mycobacterial pulmonary disease. Eur Respir J 2021;57.

21. Button B, Cai LH, Ehre C, Kesimer M, Hill DB, Sheehan JK, et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 2012;337:937-41.

22. Ramsey KA, Chen ACH, Radicioni G, Lourie R, Martin M, Broomfield A, et al. Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis. Am J Respir Crit Care Med 2020;201:661-70.

23. Button B, Boucher RC, University of North Carolina Virtual Lung G. Role of mechanical stress in regulating airway surface hydration and mucus clearance rates. Respir Physiol Neurobiol 2008;163:189-201.

24. Button BM, Button B. Structure and function of the mucus clearance system of the lung. Cold Spring Harb Perspect Med 2013;3.

25. Herrero-Cortina B, Spinou A, Oliveira A, O'Neill B, Jacome C, Dal Corso S, et al. Airway clearance techniques and exercise in people with bronchiectasis: two different coins. Eur Respir J 2023;62.

26. Coppolo DP, Schloss J, Suggett JA, Mitchell JP. Non-Pharmaceutical Techniques for Obstructive Airway Clearance Focusing on the Role of Oscillating Positive Expiratory Pressure (OPEP): A Narrative Review. Pulm Ther 2022;8:1-41.

27. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy

in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34:1086-92.

28. Basavaraj A, Segal L, Samuels J, Feintuch J, Feintuch J, Alter K, et al. Effects of Chest Physical Therapy in Patients with Non-Tuberculous Mycobacteria. Int J Respir Pulm Med 2017;4.

29. Kim HJ, Kwak N, Hong H, Kang N, Im Y, Jhun BW, et al. BACES Score for Predicting Mortality in Nontuberculous Mycobacterial Pulmonary Disease. Am J Respir Crit Care Med 2021;203:230-6.

30. Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 2013;187:197-205.

31. Hong JY, Yang GE, Ko Y, Park YB, Sim YS, Park SH, et al. Changes in cholesterol level correlate with the course of pulmonary nontuberculous mycobacterial disease. J Thorac Dis 2016;8:2885-94.

32. Chan ED, Iseman MD. Slender, older women appear to be more susceptible to nontuberculous mycobacterial lung disease. Gend Med 2010;7:5-18.

33. Martin-Romero C, Santos-Alvarez J, Goberna R, Sanchez-Margalet V. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol 2000;199:15-24.

34. Tasaka S, Hasegawa N, Nishimura T, Yamasawa W, Kamata H, Shinoda H, et al. Elevated serum adiponectin level in patients with Mycobacterium avium-intracellulare complex pulmonary disease. Respiration 2010;79:383-7.

35. Olveira G, Olveira C, Dona E, Palenque FJ, Porras N, Dorado A, et al. Oral supplement enriched in HMB combined with pulmonary rehabilitation improves body composition and health related quality of life in patients with bronchiectasis (Prospective, Randomised Study). Clin Nutr 2016;35:1015-22.

36. Bhargava A, Bhargava M, Meher A, Teja GS, Velayutham B, Watson B, et al. Nutritional support for adult patients with microbiologically confirmed pulmonary tuberculosis: outcomes in a programmatic cohort nested within the RATIONS trial in Jharkhand, India. Lancet Glob Health 2023;11:e1402-e11.

37. Youssefnia A, Pierre A, Hoder JM, MacDonald M, Shaffer MJB, Friedman J, et al. Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review. J Thorac Dis 2022;14:3575-97.

38. Jillian Kubala, Kris Gunnars. 16 Delicious High Protein Foods. Healthline; 2023 [cited 2024 APR 22]. Available from: https://www.healthline.com/nutrition/high-protein-foods.

39. Dawrs SN, Kautz M, Chan ED, Honda JR. Mycobacterium abscessus and Gastroesophageal Reflux: An In Vitro Study. Am J Respir Crit Care Med 2020;202:466-9.

40. Falkinham JO, 3rd. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009;107:356-67.

41. Bodmer T, Miltner E, Bermudez LE. Mycobacterium avium resists exposure to the acidic conditions of the stomach. FEMS Microbiol Lett 2000;182:45-9.

42. Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest 2007;131:1166-72.

43. Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med 2008;359:1700-7.

44. Falkinham JO, 3rd. Ecology of nontuberculous mycobacteria--where do human infections come from? Semin Respir Crit Care Med 2013;34:95-102.

45. Adjemian J, Olivier KN, Seitz AE, Falkinham JO, 3rd, Holland SM, Prevots DR.

Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012;186:553-8.

46. Maekawa K, Ito Y, Hirai T, Kubo T, Imai S, Tatsumi S, et al. Environmental risk factors for pulmonary Mycobacterium avium-intracellulare complex disease. Chest 2011;140:723-9.

47. Yoon JK, Kim TS, Kim JI, Yim JJ. Whole genome sequencing of Nontuberculous Mycobacterium (NTM) isolates from sputum specimens of co-habiting patients with NTM pulmonary disease and NTM isolates from their environment. BMC Genomics 2020;21:322.

48. Tzou CL, Dirac MA, Becker AL, Beck NK, Weigel KM, Meschke JS, et al. Association between Mycobacterium avium Complex Pulmonary Disease and Mycobacteria in Home Water and Soil. Ann Am Thorac Soc 2020;17:57-62.

49. Park Y, Kwak SH, Yong SH, Lee SH, Leem AY, Kim SY, et al. The Association between Behavioral Risk Factors and Nontuberculous Mycobacterial Pulmonary Disease. Yonsei Med J 2021;62:702-7.

50. Prevots DR, Adjemian J, Fernandez AG, Knowles MR, Olivier KN. Environmental risks for nontuberculous mycobacteria. Individual exposures and climatic factors in the cystic fibrosis population. Ann Am Thorac Soc 2014;11:1032-8.

51. Falkinham JO, 3rd. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011;17:419-24.

52. Guenette S, Williams MD, Falkinham JO, 3rd. Growth Temperature, Trehalose, and Susceptibility to Heat in Mycobacterium avium. Pathogens 2020;9.

53. Rodgers MR, Blackstone BJ, Reyes AL, Covert TC. Colonisation of point of use water filters by silver resistant non-tuberculous mycobacteria. J Clin Pathol 1999;52:629.

54. Cerna-Cortes JF, Cortes-Cueto AL, Villegas-Martinez D, Leon-Montes N, Salas-

Rangel LP, Rivera-Gutierrez S, et al. Bacteriological quality of bottled water obtained from Mexico City small water purification plants: Incidence and identification of potentially pathogenic nontuberculous mycobacteria species. Int J Food Microbiol 2019;306:108260.

Table 1. Non-pharmacological strategies to alter the vulnerable host phenotype against NTM-PD

Strategy	Detail
Airway clearance	Airway hydration
	Use of mechanical stress and oscillation
	Various types of airway clearance techniques
Nutritional support	Achieve higher body mass index
	Raise body fat
	Nutritional supplementation
	Be specific about nutritional tips
Management of GERD	Reduce episodes of reflux
	Smoking cessation
	Be careful about using antacids

Abbreviations: NTM-PD, nontuberculous mycobacterial pulmonary disease; GERD, gastroesophageal reflux disease.

Table 2. Methods to reduce exposure to NTM from the environment

Exposure	Methods to reduce exposure
Water	(Abruptly) Increase water heater temperature > 55~65°C
	Reduce bathroom aerosols (opening the windows or using fans)
	Short showers
	No indoor swimming pool
	Drink only boiled water
Soil	Avoid aerosolization of the soil (dampen the soil)
	Use appropriate masks

Abbreviations: NTM, nontuberculous mycobacteria.

Figure legends

Figure 1. Modifiable host risk factors for development of NTM-PD

Abbreviations: NTM-PD, nontuberculous mycobacterial pulmonary disease; GERD, gastroesophageal reflux disease.



Figure 2. Mechanisms of transmission of NTM from environment to host

Abbreviations: NTM, nontuberculous mycobacteria; GERD, gastroesophageal reflux disease; NTM-PD, nontuberculous mycobacterial pulmonary disease.